Although the mechanisms of action by which aspirin, clopidogrel and dipyridamole inhibit platelets are well characterised, their effects on soluble modulators of thrombosis, inflammation, and endothelial function have yet to assessed systematically. In this investigation aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in combination (A, C, D, AC, AD, CD, ACD) in random order for two weeks (without washout) to 11 healthy subjects and 11 patients with previous ischaemic stroke. At and patients, -3.61 (2.75) (non-significant trend). Aspirin lowered PDGF (ng/mL) in volunteers, -3.46 (1.55) (p<0.05), but not patients. Triple antiplatelet therapy was superior to dual and mono therapy in reducing vWf levels. In conclusion, antiplatelet agents have non-platelet-related effects on soluble modulators of thrombosis, inflammation, and endothelial function. In particular, dipyridamole reduces plasma vWf and clopidogrel lowers plasma PAI-1 levels. These effects may explain, in part, their roles in preventing atherothrombogenesis.
INTRODUCTION
The three antiplatelet agents, aspirin, clopidogrel and dipyridamole, are widely used for secondary stroke prevention on the basis of results from large trials and systematic reviews. We assessed the effects of aspirin, clopidogrel and dipyridamole on a panel of the above soluble markers of vascular function in normal volunteers and patients with a prior history of ischaemic stroke. We also assessed the effect of combining the three antiplatelet agents on the soluble markers since we have shown previously that three drugs may be superior to one or two in inhibiting platelet function in vitro.
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METHODS

Design
Two randomised, outcome-blinded, multiway, crossover trials of antiplatelet therapy were performed in normal volunteers and patients with prior ischaemic stroke. The study design has been published previously 16 in a report of the effect of aspirin, clopidogrel and dipyridamole on the function of circulating platelets, phagocytes and their conjugates.
Subjects
The study protocol was approved by the local Research Ethics Committee. All subjects gave written informed consent and the trials were performed according to the The drugs were given either singly (A, C, or D), in pairs (AC, AD, or CD) or all three together (ACD) in random order. 16 Normal volunteers, but not patients, were also studied off all therapy. No washout periods were used since the length of each treatment phase (14 days) exceeded the lifespan of platelets (~10 days); further, it would have been inappropriate to deprive patients of antiplatelet therapy during such periods. Randomisation was performed using a computer and the treatment codes held by the hospital's Pharmacy to ensure concealment of allocation. Blood samples were collected at the end of each two-week treatment phase. Adverse events are reported previously. 16 Subjects who withdrew from treatment were replaced to ensure that complete data were present for each person; laboratory data from withdrawing subjects are not included in the statistical analyses.
Laboratory study
Serum and plasma collected into 3.8% sodium citrate (1:9 volume) or 4.0 mmol/L EDTA were centrifuged (1,500g for 15min) within 1 hour of venepuncture. Aliquots were frozen at -80 o C and then assayed in batches using commercially available ELISA kits. CRP (high sensitivity kit, Kalon Biological, Hants, UK) and PDGF (R&D System, Abington, UK) were measured in serum; cGMP (R&D System), vWf (Corgenix, Cambridgeshire, UK), MCP-1 (R&D System) and PAI-1 (Technoclone TC, Surrey, UK)
were analysed in citrated plasma.
Plasma (citrated) nitric oxide (NOx) levels were determined from measurement of its stable end products, nitrate and nitrite, by a chemiluminescence (Sievers 280 Nitric
Oxide Analyser, Analytix Limited, County Durham, UK) method. 17 This involved injecting 10µL of deproteinised plasma samples into vanadium chloride. 18 The nitrate and nitrite present in samples were reduced to NO, and quantified from a calibration curve based on prepared concentrations of sodium nitrate.
Statistical analysis
The primary analysis compared the presence and absence of each drug on soluble markers, i.e. aspirin versus no aspirin, clopidogrel versus no clopidogrel, and dipyridamole versus no dipyridamole. Secondary analyses compared triple therapy (ACD) versus all other drugs, as before. 16 Analyses were performed using the SAS statistical package. (table 3) ; no differences in the other biomarkers were apparent. The use of triple antiplatelet therapy was not superior to mono or dual therapy with the exception that the combination of all three agents was associated with significantly lower levels of plasma vWf than dual aspirin and clopidogrel in both volunteers and patients (table   3) , a finding compatible with the above observation that dipyridamole lowers vWf levels.
DISCUSSION
These studies show that antiplatelet agents may alter soluble markers of vascular function. In particular, dipyridamole significantly reduced plasma vWf levels in both volunteers and patients with previous stroke, an effect seen previously in an independent study involving patients with ischaemic heart disease. 19 Studies in vitro and ex vivo have found that dipyridamole significantly reduces platelet adhesion to vascular sub-endothelium although the mechanism remains unclear. 20, 21 Both vWf and P-selectin are stored in Weibel-Palade body in the endothelium. 22, 23 Proinflammatory mediators activate cells causing Weibel-Palade bodies to fuse with the cell membrane resulting in the release of vWf and surface exposure of P-selectin. vWf and P-selectin are the primary molecules involved with platelet interaction with endothelium. 23, 24 In the present study we provide evidence that the inhibitory effect of dipyridamole on platelet adhesion may be mediated in part through inhibition of vWf release from endothelial cells.
Dipyridamole also appeared to lower serum CRP levels, a previously unreported finding. However, this finding was only present in patients with prior cerebrovascular disease and could simply reflect chance. Several studies reported that dipyridamole potentiates NO-induced vasodilator activity through inhibiting phosphodiesterase V activity and thereby enhancing intracellular cGMP levels. [25] [26] [27] However, we did not observe changes in plasma NOx and cGMP levels with dipyridamole.
Clopidogrel showed an inhibitory effect on plasma PAI-1 levels (significant in volunteers, non-significant in patients) but not on other biomarkers. The reduction of PAI-1 has been observed in two earlier studies 28, 29 and may be achieved partially through inhibition of platelet activity. 30, 31 Previous studies reported that clopidogrel lowers CRP levels in patients with acute vascular disease. [32] [33] [34] However, we did not confirm this observation, perhaps because CRP is an acute phase protein and is elevated significantly in acute rather than chronic vascular disease.
Aspirin reduced serum PDGF levels but only in volunteers; this finding has not been reported before and might reflect chance. A reduction in CRP with aspirin was found in an earlier study of patients with hypertension 35 but not in studies involving healthy subjects. 36, 37 Apart from differences in subjects, this positive study involved prolonged
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treatment over 18 weeks whereas aspirin was given for shorter periods (<1 month) in the above two neutral studies and ours.
We found, in secondary analyses, that plasma NOx levels were lower, and vWf levels higher, in patients with cerebrovascular disease than in volunteers. Both factors are produced by endothelial cells and the results support previous finding that endothelial dysfunction is present in patients with vascular disease. For example, patients with hypertension, hypercholesterolaemia, diabetes mellitus and previous clinical vascular events have lower NOx and elevated vWf levels. 38, 39 Similarly, acute stroke is associated with low NOx and high vWf levels. 18, 40 Although our trials were small, we used a crossover design (thereby allowing each subject to act as their own control) which considerably increases statistical power as compared with a parallel group design. Additionally, we assessed the effects of antiplatelet agents in two different sets of subjects which increases the validity of the findings. Importantly, measurements were made by one person who was blinded to treatment.
In summary, dipyridamole reduced plasma vWf levels, a measure of endothelial dysfunction, in both normal subjects and patients with previous ischaemic stroke.
Similarly, clopidogrel lowered plasma PAI-1 concentrations in both sets of subjects (significantly so in volunteers). The findings suggest that these agents have additional effects on non-platelet aspects of atherothrombogenesis, mechanisms which may explain, in part, their roles in preventing recurrent vascular events such as stroke.
The effects of these agents on other vascular risk markers such as fibrinogen and Pselectin remains to be ascertained. 
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